CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...

CCAB and Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates AUSTIN, Texas and HAMILTON, Ontario and TORONTO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc....

CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies TORONTO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB...

CCAB Signs Collaboration and License Agreement With Pionyr Immunotherapeutics Inc. to Discover Antibody Drug Development Candidates TORONTO, April 03, 2017 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB), through the University of Toronto, has granted a non-exclusive license to Pionyr...